Form 8-K · Current report
AbbVie 8-K, filed Nov 2, 2026
- Filed
- CIK
- 0001551152
- Accession no.
- 0001104659-26-121322
Summary
Jennifer L. Davis, a Class II director of AbbVie, notified AbbVie's board on October 28, 2026 that she intends to resign effective November 2, 2026, following her appointment as Chief Executive Officer of Align Technology. AbbVie said the resignation is not due to any dispute or disagreement with the company on its operations, policies, or practices.
Key points
- Jennifer L. Davis is a Class II director of AbbVie.
- Davis notified AbbVie's board on October 28, 2026 of her intent to resign effective November 2, 2026.
- She resigned in light of her recent appointment as Chief Executive Officer at Align Technology, Inc.
- AbbVie said the resignation is not the result of any dispute or disagreement with AbbVie on operations, policies, or practices.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
From the filing
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers On October 28, 2026, Jennifer L. Davis, a Class II director of AbbVie Inc. (“AbbVie”), notified the Company’s Board of Directors (the “Board”), of her intent to resign from the Board, effective November 2, 2026, in light of her recent appointment as Chief Executive Officer at Align Technology, Inc. Her resignation as a director is not the result of any dispute or disagreement with AbbVie on any matter relating to the operations, policies or practices of AbbVie.
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.